Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer

Jeffrey A. How, Shrina Patel, Bryan Fellman, Karen H. Lu, Patrick Hwu, Lois M. Ramondetta, Shannon N. Westin, Nicole D. Fleming, Pamela T. Soliman, Amir A. Jazaeri

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences